questionText: To ask the Secretary of State for Health and Social Care, what steps he is taking to ensure consistent national adoption of post-transplant cyclophosphamide (PTCy) for patients receiving mismatched unrelated donor haematopoietic stem cell transplants.
answerText: Clinical decisions regarding graft-versus-host disease prophylaxis, including the use of post-transplant cyclophosphamide (PTCy), are made by specialist transplant clinicians in accordance with the latest clinical evidence and professional guidance. The D...
heading: Stem Cells: Transplant Surgery